Skip To Content

Dutch Team Investigates Cancer Risk

A team of researchers with the University of Amsterdam Academy Medical Center has rejected the notion that Jewish genetics are at the root of an increased risk of cancer among sufferers of Gaucher disease.

Gaucher ? a fat-storage disease ? is found most commonly among Ashkenazic Jews. The medical community has known for more than three decades that Jewish Gaucher patients are more susceptible to blood-related cancers than those without the disease.

What the new Dutch study shows, however, is that Jewish Gaucher sufferers are no more likely to develop blood cancer than non-Jews afflicted with the disease.

To eliminate Jewish genetics as a possible cause of the elevated cancer risk, the team created a sample made up primarily of non-Jews.

?In the previous study, all the participants were Jewish,? said Maaike de Fost, one of the researchers on the Dutch team. ?In our study, less than 10% of the patients were known to be of Ashkenazi Jewish descent.?

The study showed that Gaucher patients ? both Jewish and non-Jewish ? are 12.7% more likely than the population as a whole to develop blood-related cancers.

?This means that the previously found increased risk of developing cancer cannot be attributed solely to ethnic origin, but ? at least, for a large part ? to having Gaucher disease,? she said.

De Fost hopes the team?s findings will lead to more studies that shed light on changes associated with and resulting from Gaucher. In the meantime, while hematologists and oncologists continue to search for preventive measures, she recommends that Gaucher patients be cognizant of the cancer risks associated with their disease, so as to allow for the possibility of early detection.

?Multiple myeloma is by no means an easy thing to treat,? she said. ?It is a very nasty form of cancer, but at the beginning stages there are some treatments.?

?Elisha Sauers

For more information on extraneous health risks related to Gaucher disease, visit the National Gaucher Foundation Web site,

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly. 

— Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.